Dr. Mark Warren, M.D.

Medicare patients and services

Medicare patients, 2024

925

Services billed

55,297

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 199 payments worth $128,259 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 22 industry-funded studies in 2025, from 13 companies. The companies reported $500,365 in research payments for these studies, mostly to the institutions running them.

• A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc. · Active, not recruiting · NCT06345339
• A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
  Amgen Inc.
• A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
  Boehringer Ingelheim Pharmaceuticals, Inc.
• Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism
  Alexion Pharmaceuticals, Inc.
• PaTHway TRIAL
  Ascendis Pharma Endocrinology Inc
• A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
  AstraZeneca Pharmaceuticals LP
• M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
  AbbVie Inc.
• Study name not reported
  Novo Nordisk As
• A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Greenville

• Madhavi Averneni, MD
• Mohammad R. Azad, MD
• Fiona Cook, MD
• Moahad S. Dar, M.D.
• Regina Dodis, D. O.
• Almond J. Drake III, MD
• Matthew R. Hager, M.D.
• Caroline M. Houston, M.D.